GLP-1 Medication Safety Information

Last Updated: February 10, 2026

IMPORTANT: If you experience a medical emergency, call 911 or go to the nearest emergency room immediately.

Black Box Warning

This warning applies to all GLP-1 medications including Ozempic®, Rybelsus®, Mounjaro®, and compounded alternatives.

GLP-1 receptor agonists are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). In animal studies, GLP-1 receptor agonists caused thyroid C-cell tumors. It is unknown whether these drugs cause thyroid C-cell tumors, including medullary thyroid carcinoma, in humans.

When to Seek Immediate Medical Attention

Contact your healthcare provider or seek emergency medical attention immediately if you experience any of the following:

Thyroid symptoms: A lump or swelling in your neck, trouble swallowing, hoarseness, or shortness of breath
Pancreatitis symptoms: Severe pain in your stomach area (abdomen) that will not go away, with or without vomiting
Gallbladder problems: Pain in the upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools
Kidney problems: Decreased urination, swelling in your legs or feet, or signs of dehydration from severe nausea, vomiting, or diarrhea
Vision changes: Changes in vision, especially if you have diabetes
Severe allergic reactions: Swelling of the face, lips, tongue, or throat; difficulty breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or rapid heartbeat
Severe gastrointestinal symptoms: Persistent or severe nausea, vomiting, diarrhea, or constipation

Common Side Effects

The most common side effects of GLP-1 medications include:

Nausea
Constipation
Vomiting
Diarrhea
Abdominal pain
Headache
Fatigue
Altered taste
Decreased appetite
Dizziness
Injection site reactions

Semaglutide (Ozempic® & Rybelsus®)

Important safety information specific to semaglutide:

Stop using semaglutide at least 2 months before a planned pregnancy
Do not use if you are pregnant or breastfeeding
May cause severe allergic reactions
May affect the absorption of other oral medications due to delayed gastric emptying

Tirzepatide (Mounjaro®)

Important safety information specific to tirzepatide:

Stop using tirzepatide at least 2 months before a planned pregnancy
Use non-oral contraception methods or switch to a backup method during treatment, as tirzepatide may reduce the effectiveness of oral contraceptives
May affect the absorption of other oral medications due to delayed gastric emptying
Has the same serious side effect profile as semaglutide, including risks of pancreatitis, gallbladder problems, and kidney issues

Compounded Medications

Although compounded drugs are permitted to be prescribed under federal law, they are not FDA-approved and do not undergo safety, effectiveness, or manufacturing review by the FDA. Compounded medications are prepared by licensed compounding pharmacies in FDA-regulated facilities. The decision to prescribe compounded medications is made by your licensed healthcare provider based on their clinical judgment.

Drug Interactions

GLP-1 medications may interact with other medications you are taking, including:

Insulin and other diabetes medications (may increase risk of low blood sugar)
Sulfonylureas (may increase risk of hypoglycemia)
Thyroid medications
Warfarin and other blood thinners
Oral medications that require rapid absorption (delayed gastric emptying may affect absorption)

Tell your healthcare provider about all medications, vitamins, and supplements you are currently taking.

FDA Adverse Event Reporting

You are encouraged to report adverse events or side effects to the FDA. Reports can be submitted at:

Phone: 1-800-FDA-1088
Online: https://www.fda.gov/medwatch

Contact Information

Modern Metabolic Medicine, Inc.
1811 Silverside Road, Suite 260
Wilmington, New Castle County, Delaware 19180
Email: hello@snagrx.com
Phone: (844) 357-3601